5.84
-0.07 (-1.10%)
| Penutupan Terdahulu | 5.90 |
| Buka | 5.94 |
| Jumlah Dagangan | 3,241,132 |
| Purata Dagangan (3B) | 6,084,954 |
| Modal Pasaran | 2,031,758,592 |
| Harga / Jualan (P/S) | 14.49 |
| Harga / Buku (P/B) | 6.43 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Nuvation Bio Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.50 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.14% |
| % Dimiliki oleh Institusi | 62.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2026 | 25,954,439 |
| Omega Fund Management, Llc | 31 Mar 2026 | 8,081,089 |
| Laurion Capital Management Lp | 31 Mar 2026 | 7,822,638 |
| Redmile Group, Llc | 31 Mar 2026 | 3,153,256 |
| Tang Capital Management Llc | 31 Mar 2026 | 3,149,557 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |